Keywords
adolescents and young adults
tyrosine kinase inhibitors
How to Cite
Abstract
Chronic myeloid leukemia (CML) has been described since its onset as a disease of the sixth decade of life; however, it can be diagnosed at any age.
Adolescents and young adults (AyA) with cancer are a unique population that faces multiple challeng es during this stage of life that will condition their clinical outcomes. The impact of the disorders in the psycho-social sphere is considerably higher than in other age groups and is closely related to high levels of "non-adherence" rate. Although AyA with CML have not been studied in prospective clinical trials yet, the results of the available publications report a more aggressive clinical presentation, with lower response rates but no impact on overall survival (OS).
In the era of molecular targeted therapy, benefits are present in all age groups and remission is possible, even after the suspension of tyrosine kinase inhibitors (TKI). A different therapeutic approach for AyA is needed, with emphasis on adherence and adapting the treatment objectives to the fact that AyA could be candidates for ITK discontinuation in a near future. This article reports a literature review, the data
available in international reports as well as the experience of our institution focused on clinical presentation and response to treatment of AyA population with CML.
References
1. Deininger MWN. Chronic Myeloid Leukemia. In: Wintrobes’s Clinical Hematology.13th edition. Lippincott Williams and Wilkins 2014. p 1705-1719.
2. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. Version 4. 2018. Enero 2018.
3. Reports on Cancer. Cancer Stat Facts: Leukemia – Chronic Myeloid Leukemia (CML). SEER - Surveillance, Epidemiology, and End Results Program. En: https://seer.cancer.gov/statfacts/html/cmyl.html.
4. Husson O, Huigjens PC, van der Graff WTA. Psychosocial Challenges and Health-Related Quality of Life of Adolescents and Young Adults with Hematologic Malignancies. Blood 2018; 132: 385-392.
5. NCCN Clinical Practice Guidelines in Oncology. Adolescent and Young Adult (AYA) Oncology. Version 2. 2018. Octubre 2017.
6. Wood W, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood 2011; 117 (22): 5803 – 5815.
7. NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. Version 4. 2018. Enero 2018.
8. Kalmanti L, Saussele S, Lauseker M et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 2013
9. Castagnetti F, Guggliotta G, Baccanari M et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology 2015;26 (1): 185–192.
10. Latagliata R, Breccia M, Carmosino I et al. Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: the Younger, the Later, the Worse? Eur J Haematol 2018.
11. Baccanari M, Deininger MW, Rosti G et al. European LeukemiaNet recommendations for the managemente of chronic myeloid leukemia: 2013. Blood 2013;122 (6): 872-884.
12. Huang X, Cortes J, Kantarijian H. Estimations of the increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy. Cancer 2012; 00:1-5
13. Cortes J. Introduction to a review series on Adolescent and Young Adult Malignant Hematology. Blood 2018; 132: 345-346
14. Reports on Cancer. Cancer Stat Facts: Cancer of any site. SEER - Surveillance, Epidemiology, and End Results Program. En: https://seer.cancer.gov/statfacts/html/all.html.
15. Millot F, Guilhot J, Suttorp M et al. Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents. Haematologica 2017; 102
16. Muffly LS, Hlubocky F, Gomez J et al. Suffering Before the Cure: Evaluation Of Psychological Morbidities In Adolescents and Young Adults With Hematologic Malignancies In Early Survivorship. Blood 2013; 122: 771.
17. Hocchaus A, Saglio G, Hughes TP et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016
18. Geissler J, Sharf G, Bombaci F et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol 2017.
19. Marin D, Bazeos A, Mahon FX et al. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. J Clin Oncol 2010; 28 (14): 2381-2388.
20. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113 (22): 5401-5411.
21. Pemmaraju N, Cortes J. Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. Acta Haematol 2014; 132: 298–306.
22. Aguerre L, Moiraghi B. Leucemia mieloide crónica y embarazo en la era de las terapias blanco-moleculares. HEMATOLOGÍA 2016; 20 (3):323 – 333.
23. Palani R, Milojkovic D, Apperley J. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015; 94 (2): 167–176.
24. Chang X, Zhou L, Chen X et al. Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase. Targ Oncol 2017.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar